Kyverna Therapeutics Narrows Loss as R&D Spending Drops 31%
The cell-therapy biotech posted a $38.3 million net loss in the second quarter, down from $42.1 million a year earlier, while securing FDA RMAT designation for its lead candidate in multiple sclerosis.
Kyverna Therapeutics (KYTX), a clinical-stage cell-therapy company, reported a narrower second-quarter net loss as steep cuts to research spending more than offset a rapid expansion of its executive ranks ahead of a planned commercial push.
The results arrived alongside a regulatory milestone: the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Kyverna's lead candidate, miv-cel, in non-active secondary progressive multiple sclerosis, broadening the therapy's potential indication landscape beyond what the company had previously disclosed.
Research and development expenses fell 31% year over year to $24.8 million in the three months ended June 30, down from $35.8 million in the same period a year ago and also lower sequentially from the $30.1 million implied by first-quarter figures. General and administrative costs moved in the opposite direction, surging 72% to $14.8 million from $8.6 million, reflecting the hiring of a chief financial officer, chief commercial officer, and chief legal and compliance officer during the quarter. Total operating expenses still declined 11% to $39.6 million, from $44.4 million a year earlier.
The net loss narrowed to $38.3 million, or 63 cents a share, compared with $42.1 million, or 97 cents a share, in the second quarter of 2024. The per-share improvement was amplified by a 41% increase in weighted-average shares outstanding, which rose to 60.9 million from 43.2 million. Interest expense climbed to $674 thousand from $14 thousand a year earlier, reflecting borrowings under a loan facility with Oxford Finance.
Kyverna's cash position declined meaningfully in the first half of the year. Cash, cash equivalents, and marketable securities stood at $199.4 million at June 30, down 29% from $279.3 million at the end of 2023, representing a burn of roughly $79.8 million over six months. The company reiterated that its operating runway extends into 2028, consistent with prior guidance.
The C-suite buildout signals Kyverna's intent to lay commercial groundwork while its pipeline advances through mid-stage trials. The RMAT designation for miv-cel in naSPMS could provide the company with additional regulatory flexibility, including the potential for rolling review and early interactions with the FDA on trial design.
With R&D spending declining and administrative costs rising as the organization matures, Kyverna is navigating the transition common to late-clinical-stage biotechs: tightening the research budget while investing ahead of a possible product launch. The roughly $200 million cash cushion and reiterated 2028 runway give the company room to advance its programs, though the pace of spending will remain a key variable for investors tracking the path to commercialization.